Generic semaglutide availability in India

very informative article in the New York Times today on March 19th Ozempic Is About to Go Generic for Billions of People In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions SUMMARY FOR BROWN HEARTS 1. Novo Nordisk is losing patent protection for semaglutide in several major countries, opening the door to generic Ozempic/Wegovy in places that together represent about 40% of the world’s population. 2. The first generics are expected in India immediately, with China, Canada, Brazil, Turkey, and South Africa likely to follow in the coming months. 3. This could dramatically improve access, since semaglutide has been too expensive for most patients outside wealthy groups and high-income countries. 4. India and China alone represent a massive potential market, with more than 800 million adults who are overweight or obese and over 360 million adults with diabetes. 5. Analysts expect generic prices could eventually fall to around $15 per month, far below current branded prices such as about $349 per month for higher-dose Wegovy in the U.S. without insurance. 6. Wider availability could expand use not only for diabetes and obesity treatment, but also for cardiovascular prevention, since semaglutide has been shown to reduce heart attacks and strokes. 7. The drugs are helpful but not perfect: some patients stop because of side effects like nausea, vomiting, and constipation, though severe reactions are uncommon. 8. Public health advocates hope cheaper generics will push national insurance systems to start covering these drugs, especially where cost has been the main barrier. 9. Patent expiry adds pressure on Novo Nordisk, which is already facing competition from Eli Lilly and from copycat compounded versions in the U.S.; Novo has tried legal action and price cuts to defend its market. 10. Generics may also spread to poorer countries where Novo never sought patents, and researchers estimate semaglutide could potentially be mass-produced for as little as $3 per month per patient.